BioCardia announces commercial availability of Morph DNA product family

BioCardia (BCDA) announced the commercial availability of its Morph DNA steerable introducer product family, currently utilized in the Company’s ongoing cell-therapy clinical trials. “Our team is exploring an initial sales pipeline organically, without expending the operating costs associated with engaging a direct sales force or third-party medical device commercial partners.” said BioCardia CEO, Peter Altman, PhD. “We look forward to demonstrating the value of the Morph DNA product family to physicians for procedures throughout the vascular system.”